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Abstract: Human milk oligosaccharides have been recognized as an important, functional biomolecule
in mothers’ milk. Moreover, these oligosaccharides have been recognized as the third most abundant
component of human milk, ranging from 10–15 g/L in mature milk and up to and over 20 g/L
reported in colostrum. Initially, health benefits of human milk oligosaccharides were assigned via
observational studies on the differences between breastfed and bottle fed infants. Later, pools of milk
oligosaccharides were isolated and used in functional studies and in recent years more specific studies
into structure–function relationships have identified some advanced roles for milk oligosaccharides
in the healthy development of infants. In other research, the levels, diversity, and complexity of
human milk oligosaccharides have been studied, showing a wide variation in results. This review
gives a critical overview of challenges in the analysis of human milk oligosaccharides. In view of
the myriad functions that can be assigned, often to specific structures or classes of structures, it is
very relevant to assess the levels of these structures in the human milk correctly, as well as in other
biological sample materials. Ultimately, the review makes a case for a comparative, inter-laboratory
study on quantitative human milk oligosaccharide analysis in all relevant biological samples.
Keywords: human milk oligosaccharides (hMOS); mass spectrometry; quantitative analysis;
lactation; preterm; high pH anion exchange chromatography with pulsed amperometric detection
(HPAEC-PAD); Secretor; Lewis
1. Introduction
Human milk is considered the best source of nutrition for growing infants by the World Health
Organization (WHO). Exclusive breastfeeding for six months is the optimal way of feeding infants.
Thereafter, infants should receive complementary foods with continued breastfeeding up to two years
of age or beyond, and it is recommended to exclusively breastfeed for six months. Contrary to cows’
milk and other dairy sources, human milk contains non-lactose oligosaccharides in very high quantities,
10–15 g/L in mature milk and even over 20 g/L in colostrum [1,2]. The complexity of human milk
oligosaccharides (hMOS) is also much higher than observed for the oligosaccharides in the milk of most
other mammals [3–5]. There are many functional properties assigned to hMOS, including prebiotic
properties, modulation and maturation of the infant’s immune system, gut (barrier) development, and
anti-pathogenic activities [6–9].
In 1952 Kuhn described the vitamins of human milk [10], which included a novel factor that
influenced the growth of bifidobacteria [11–13]. Kuhn discovered that the bifidus factor of human
milk was a carbohydrate, containing nitrogen. The carbohydrate fraction consisted of oligosaccharides
constructed of galactose, glucose, fucose, and N-acetylglucosamine [14]. Further studies showed that
only GlcNAc containing oligosaccharides that were effective bifidus factors [14]. In the following
years, several different structures were elucidated [15–19]. Later studies have identified and annotated
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over 150 structures [20]. From the identified structures some general observations were made on the
biosynthetic rules, and some interpretations could be made on enzymes involved [20,21].
Over time, more studies into the benefits of human milk in general, and hMOS specifically, were
performed [7,8,22–25]. These studies show that sometimes there are very specific functions to very
specific hMOS. As an example, there is a growing case for di-sialyl-lacto-N-tetraose (DS-LNT; Figure 1)
in prevention of necrotizing enterocolitis (NEC) in preterm infants [26–29], with a lesser functionality of
2′-fucosyllactose (2′-FL) [28]. Lewisx bearing structures, particularly lacto-N-fucopentaose III (LNFP III;
Figure 1), were associated with reduced risk of transfection of HIV from seropositive mothers to their
infants [30–32], with a suggested dose-dependence. There are many other specific structure–function
relationships observed that are very extensively reviewed elsewhere [9,22,33].
With the interest of unravelling the complex functionalities of hMOS, and to elucidate
structure–function relationships, it is increasingly important to perform thorough quantitation of
specific structures, not only in milk, but also other sample matrices. So far, hMOS have been observed
not only in the mother’s milk, but also in the feces of infants up to six months post-partum [34–37],
the blood stream of breastfed infants, and the urine of breastfed infants [38,39]. It has been shown that
many hMOS survive the GI tract intact in the earliest phases of lactation and are in ample supply in
the feces [36,40–43]. Over time, the hMOS profile of feces changes and correlations have been made
with the development of the microbiome [35,37,41,44]. The hMOS composition of the feces is very
variable among individuals. Some infants at one-month age have no detectable levels of hMOS in the
feces, while others show a very complete hMOS profile [36,41,44].
Recent studies have also shown hMOS present in the blood stream of pregnant women, [45,46]
and in the amniotic fluid [47]. Some of the functions of hMOS are linked to specific structures as
described above. To effectively determine whether a structure is present in sufficient concentration to
affect its proposed functionality, it is important to understand actual levels of hMOS in all different
biological matrices where hMOS may be functional.
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Figure 1. Overview of main human milk oligosaccharides (hMOS) structures for which quantitative
data are available. Structures are drawn in the Consortium for Functional Glycomics graphical notation,
and a legend for the structural elements is added [48].
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This review will focus on the different methods of hMOS analysis in different matrices. An analysis
of the different pitfalls of certain approaches will be made. Since most of the work so far has been
done on milk, the main portion will discuss the differences in approaches and results on human milk.
To place the analytical challenges and result variation into perspective, it is also important to discuss
the natural sources of variation in hMOS concentrations.
2. Factors Influencing hMOS Composition
Studies found that there are many factors influencing the levels of hMOS observed in milk.
The first source of difference that was identified is the time post partum of lactation. Colostrum is
consistently found to be richer in hMOS than mature milk [1,2]. More detailed studies over the course
of lactation have consistently shown that hMOS are not constant over the course of lactation [49–53].
Also, differences were described between mothers delivering term or preterm [54,55]. Other studies,
comparing the milk of mothers delivering preterm with term pregnancies, showed no significant
differences between the two [56,57]. A recent study showed that there were only minimal differences
between term and preterm mothers if you compare the milk in days post-partum [53]. If you consider
the time post-menstrual, and thus compare it with the similar infant developmental stage, there are
significant differences [53].
Genetic diversity within a population is also a potential source of differences in hMOS
composition. One major example is the maternal Secretor- and Lewis-based blood groups. These blood
groups are based on genetic variants of the Secretor (α1,2-fucosyltransferase; FucT2) and Lewis
(α1,3/4-fucosyltransferase; FucT3) genes [58–62]. These two FucT enzymes are also responsible for the
transfer of fucose to hMOS [21,63,64].
The majority of most populations have both genes functional and active, but in some individuals
one or both of the genes contain a single-nucleotide mutation that disables the gene. This results
in four so-called milk groups: Se+Le+, which has both genes active, se−Le+ with a defective FucT2
gene, but a functional FucT3 gene, Se+le− with a functional FucT2 and a SNP in FucT3, and finally
the rare se−le− individuals that have defects in both genes (Figure 2). Interestingly, individuals with a
defect in the FucT3 gene are still capable of synthesizing hMOS containing (α1–3)-linked fucose, like
3-fucosyllactose (3-FL) and lacto-N-fucopentaose III (LNFP III), but no longer (α1–4)-linked fucose
structures, like lacto-N-fucopentaose II (LNFP II; Figure 1). In a few studies on Asian populations,
individuals have been observed with neither (α1–3)- or (α1–4)-linked fucose, suggesting that the (α1–3)
backup in Lewis-negative individuals is mediated through a specific fucosyltransferase gene, rather
than side-activity of several or all (α1–3)-specific fucosyltransferases (FucT4,5,6,7 and 9) [36,65].
Several studies report significant differences in specific, or total hMOS between the milk groups.
Most frequently reported are significant increases in lacto-N-tetraose (LNT) levels in so-called milk
group 4 individuals, that are defective in both FucT2 as well as FucT3. Also, non-secretor individuals,
that are defective in FucT2, seem to have higher levels of LNFP II and particularly LNFP III, which
was postulated as the effect of lower competition for the precursors LNT and lacto-N-neo-tetraose
(LNnT) (Figure 1). There is a specific competition between FucT2 and FucT3 for acceptor molecules,
with FucT3 blocking activity of FucT2, but not vice versa. LNFP I can still be converted to LNDFH I
by activity of FucT3, while LNFP III cannot be converted by FucT2 (Figure 2). Moreover, there were
observations that 2’-FL and LNFP I are more abundant in milk group 3 individuals, that are FucT3
deficient, than in milk group 1 participants that have both enzymes active [54,66]. The increased levels
of LNFP I in milk group 3 individuals, compared to milk group 1 individuals, could be the result of
acceptor competition between FucT2 and FucT3 for the LNT precursor, although LNT is one of the
major hMOS. In the case of 2′FL, however, this is clearly not the case, since lactose is present in such
excess. Samuel et al. (2019) postulated that it is more likely a result of competition between FucT2 and
FucT3 for the GDP-fucose donor substrate, which is limiting [66]. There are also studies indicating
that sialyl-lactose is more abundant in non-Secretor individuals. Here, the same statement is true,
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that lactose is present in excess. However, this does not explain the observed difference in levels of
sialylated hMOS between Secretors and non-Secretors [54,66–68].
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Figure 2. (A) Proposed biosynthesis pathways of main core structures adapted from [21] (B) biosynthetic
pathways of fucosylated epitopes mediated by FucT2 and FucT3; and (C) overview of H-antigen and
Lewis epitopes present in milk of Secretor (Se+), non-Secretor (se−), Lewis positive (Le+) and negative
(le−) individuals; (D) proposed biosynthesis of sialylated structures.
There are also studies reporting significant levels of 2′-FL and LNFP I present in milk from
non-Secretor individuals. Some reporting up to 25% remaining 2′-FL [69,70]. In a study by
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Nakhla et al. (1999), where Secretor and Lewis status was determined by agglutinin screening
of saliva samples, it was shown that 2′-FL levels within Secretor mothers milk can be very low [57].
There seemed to be a division between mothers producing 1200–1700 mg/L 2′-FL and a group
producing 300–400 mg/L 2′-FL, with few in between. In this study, mothers tested as Lewis-positive
showed LNFP II levels between 27–147 mg/L, with one outlier at 1338 mg/L. Lewis-negative mothers
showed no detectable levels of LNFP-II. Other studies have seen clear examples of non-Secretors or
Lewis-negative individuals where no detectable levels of 2′-FL or LNFP I or LNFP II, respectively, were
observed [21,36,56,71–74]. Interestingly, one paper shows a unique example of a mother that does not
produce and 2′-FL during the first nine months of lactation, but then shows a slow increase to normal
levels of 2′-FL [75]. In a later study by De Leoz et al. (2012) studying mothers that delivered preterm
over time, showed two participants that had no detectable 2′-FL at the first time-point, but had some
2′-FL in one or more of the later time-points. In that same study one other patient had normal levels of
2′-FL detected in the milk, except for one time point in the middle of the studied time-period, where
no 2′-FL was detected [55]. These observations indicate that it may not always be correct to make
assumptions on Secretor status, based on hMOS composition at one singe time-point.
Finally, strong evidence exists for geographical differences in hMOS composition of the milk.
Primarily, differences in Lewis and Secretor status was observed between regions. In Caucasian studies
initially ~75%–80% secretor and ~90% Lewis-positive individuals were found. Since there is a large
distance between the genes (FucT2 19q13.3, FucT3 19p13.3, >40 M base pairs) on the chromosome
the genetic variations are not interdependent [76,77]. This result was shown in 69% of Se+Le+, 20%
of se−Le+, 10% of Se+le−, and 1% of se−le− individuals. Recent studies, analyzing milk from different
geographical locations showed that there are not only differences between countries (Table 1) [78–80],
but there can also be differences within a country [36,68]. Not only are the levels of Secretor and Lewis
status differentially distributed geographically, but also the general balance of milk oligosaccharides
may be different.
Table 1. Overview of geographical distributions of Secretor (Se) and Lewis (Le) occurrence.
Country n= Se (%) Le (%) Reference
Brazil 77 88 88 [81]
Burkina Faso 53 76 87 [79]
Chile 44 84 80 [78]
China 32 78 91 [78]
China 540 79 nd [49]
China Sohhot 30 80 94 [82]
Ethiopia Rur 40 65 nd [68]
Ethiopia Urb 40 78 nd [68]
France 22 91 68 [78]
France 83 87 89 [66]
Gambia Rur 40 65 nd [68]
Gambia Urb 40 85 nd [68]
Germany 18 83 100 [78]
Germany 50 78 89 [64]
Germany 30 83 90 [71]
Ghana 40 68 nd [68]
Italy 63 66 84 [54]
Italy 29 86 86 [78]
Italy–Sicily 50 77 97 [79]
Kenya 42 81 nd [68]
Malaysia 20 65 90 * Unpubl
Mexico 316 100 74 [83]
Mexico 156 100 83 [78]
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Table 1. Cont.
Country n= Se (%) Le (%) Reference
Netherlands 32 72 88 [73]
Netherlands 121 73 nd [41]
Peru 43 98 nd [68]
Philippines 22 46 96 [78]
Portugal 95 66 86 [66]
Romania 40 90 93 [66]
Singapore 26 72 96 [78]
Spain 32 66 81 [56]
Spain 41 76 nd [68]
Sweden 24 79 nd [68]
Sweden 40 90 95 [66]
Switzerland 61 79 94 [53]
USA 79 68 90 [78]
USA Calif 19 95 nd [68]
USA Wash 41 68 nd [68]
Vietnam 101 60 87 [36]
Ho Chi Minh 18 72 89 [36]
Ha Long Bay 20 80 90 [36]
Hanoi 21 33 86 [36]
Phu Tho 22 64 91 [36]
Tien Giang 20 55 80 [36]
Some regions have been analyzed by multiple studies. Rur indicates rural environment and Urb indicates urban
environment, nd indicates that no data were available. * indicates an unpublished sample set from our lab.
3. Analysis of hMOS
Glycan analysis is notoriously difficult, for protein glycosylation studies double-blind
inter-laboratory examinations have shown that different labs, with different methods will arrive
at different results and conclusions. This led to the recommendation to be very specific in methodology
when reporting glycan data. So far, it has proven difficult to standardize methods between labs.
Thurl et al. (2017) have evaluated hMOS literature, to find the range and average values of
oligosaccharides in human milk [1]. They found 129 eligible studies in total, of which only 21 qualified
to be taken into account. Criteria included (i) absolute quantitation of single structures, (ii) milk samples
from individual, healthy mothers, (iii) documentation of pregnancy duration, (iv) documentation of
lactation days. Studies were excluded when samples were pooled, or lactation time for sampling was
not clearly stated. Also, mean values were reported and concentration values should be reported with
at least n = 2 samplings per time-point. Most of the excluded studies reported no real quantitation, but
relative abundances, reported n = 1 data or did not report on Secretor status when reporting neutral
oligosaccharide quantities.
3.1. Qualitative Analysis
There are many studies on hMOS that do not look at quantitation of specific hMOS [36,84,85].
Some of these studies do provide general quantitation of total hMOS [86], or relative abundances of
hMOS or hMOS classes [55,70,87–89]. Many studies also specifically aim to identify novel hMOS [90–95],
or identify as many hMOS in a milk sample as possible [37,69,87,96]. While these studies provide insight
into the complexity of hMOS and are able to assess the inter-individual differences in oligosaccharide
composition of milk and other biological samples, they do not provide detailed insight into the absolute
quantities, which is most relevant to understand functional properties of hMOS. Many of the qualitative
studies have assessed the distribution of so-called milk groups [21,36,64,67,73], based on the presence
of activity of FucT2 and FucT3 (Figure 2).
In case of shotgun-MS analysis, aiming to identify as many structures as possible in one sample,
one of the difficulties is in the identification of the different isomers. For MALDI–TOF-MS fingerprint
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screening, it is not possible to separate isomers, like LNT and LNnT, or make distinction between
isomers of LNFP, since they all have the same monosaccharide composition and mass (Figure 1).
Taking specific steps to label Neu5Ac via linkage-specific esterification it is possible to separate
Neu5Ac(α2–3) from Neu5Ac(α2–6) in a MALDI–TOF-MS approach [97,98]. Only with fragmentation
studies in MS/MS it would be possible to distinguish between isomers with the same linkage type, but
at different positions, e.g., LST b from LST c (Figure 1). By coupling the mass spectrometer to a form of
liquid chromatography another dimension can be added and elution time adds information about
identity, allowing separation between, e.g., LNT and LNnT [69,87,96]. Still, identification of structures
for which no standard is available, or the elution time is unknown is difficult. Although MS/MS can
help distinguish some structural elements, particularly branch-points, it is still not straightforward
to attach exact linkage positions. Some researchers have tackled this challenge by adding sequential
exoglycosidase profiling to the analysis, to help identify structures (Figure 3) [87]. It is important
to take care in tuning the exoglycosidase assays, since most enzymes have either cross-reactivity at
a lower rate for other structural elements or have a minor contamination with another glycosidase
enzyme that performs such side-activity at a low rate. Adding too much enzyme or incubating too long
may lead to incorrect conclusions. Alternatively, too short assays or employing too little enzyme has
the risk of leaving partially undigested peaks left, leading to potential errors in identification as well.
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3.2. a titative alysis
ata et al. (1969) showed a first quantitation of specific oligosaccharides, ranging from
30–700 mg/L for LNT, 0–250 mg/L for LNFP I, and 160–850 mg/ for LNFP II. Difucosylhexaoses were
also quantified together betwee 0 and 750 mg/L [65]. In this study, samples of hu an milk from
nine donors were processed by centrifugation to remove fat, followed by a cold etha ol reci itati
overnight to remove a large part of the lactose fraction as well as proteins. Using a size-exclusion
chromatography step on Sephadex G25 the hMOS were fractionated further and ultimately analyzed.
Quantitation was performed by paper chromatography and chemical staining. This is also one of
the first papers showing a difference in hMOS composition between people with a Secretor or a
non-Secretor blood group.
In later studies of hMOS, there have been several routes developed for the specific quantitation of
hMOS structures in milk. In most cases the hMOS are first isolated from the milk, to avoid interference
of highly abundant lactose, lipids and proteins in the milk. These methods are in some cases very
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elaborate with multiple precipitation, filtering or solid-phase extraction steps [46,65,75,101,102], and in
some cases no more than direct fluorescent labeling followed by an online clean-up step in the ultra-high
pressure liquid chromatography (UPLC) setup [103,104]. There are also examples of laboratories
using a single clean-up step, e.g., acetonitrile precipitation [50,54,105], or solid-phase extraction [56],
followed by analysis. Ultimately, the hMOS need to be detected, which can be achieved by adding a
label allowing UV or fluorescence detection or by label-free mass spectrometry (MS) based methods.
Some studies employed 1D 1H NMR spectroscopy to analyze hMOS, either qualitatively [73] or in
metabolomics approaches quantitatively [106,107]. It has been noted before that there are significant
differences between studies on reported hMOS levels [2,56]. Some studies report values around
4–7 g/L [41,49,108], while other studies report values over 20 g/L [50,54,105]. The differences may be
the result of methodological differences, but also due to the natural variation in milk composition.
There are multiple factors influencing the amount and composition of hMOS, including blood-group
genetics [63,64], time post-partum [53,54,56], geographical influences [36,68,109], and possibly even
the gender of the infant [108].
3.2.1. Sample Preparation
Prior to analysis, most studies use several steps of sample preparation. There are many different
routes available in literature, but there are some frequently employed steps. The milk contains three
main fractions of compounds that potentially interfere with hMOS analysis, i.e., fat, protein, and
lactose. In some studies milk salts are also considered an interfering factor and specific steps for salt
reduction are taken.
Solid Phase Extraction
There is a multitude of solid-phase materials for extraction of metabolites. In hMOS studies
there are two materials used, C18 solid-phase extraction (SPE) resin and porous graphitized carbon
(PGC). While some studies employ only graphitized carbon [41,56], there are several other studies
that use a combination of both SPE materials in their sample preparation [30,46,68]. Removal of
lipids and peptides is achieved by binding to the C18 column, while the oligosaccharides have little
affinity to the resin and wash through the column. The PGC is based on complex interactions with
graphite and carbohydrates, both involving the hydrophilic character of carbohydrates, as well as
hydrophobic stacking [110]. To date, the exact interaction between the resin and oligosaccharides is
not well understood. One of the earliest studies already used graphitized carbon to capture hMOS
from milk [10]. The graphitized carbon also traps proteins but has such strong affinity that the proteins
are not eluted together with the hMOS. To avoid overloading standard PGC-SPE columns with protein,
and then losing the lower-affinity hMOS, it might help reducing the protein load beforehand. A first
SPE step with C18 can help to reduce the protein load prior to the PGC-SPE step. However, PGC-SPE
columns have almost no retaining capacity for monosaccharides and most disaccharides also pass
through with minor affinity [110]. This also results in a significant reduction of lactose in the samples,
often sufficient to eliminate the interference of lactose in further analysis. One recent study on hMOS
showed that 3-FL also eluted from the column very easily and is specifically lost in hMOS isolation
using PGC-SPE [111]. This also explains why some papers employing PGC-SPE report lower 3-FL or
no 3-FL in their hMOS profiles than others [55,56,69,70,87,112,113]. So far, a few studies have covered
this by alternative quantitation of 3-FL separately from the total pool of hMOS that were isolated with
PGC-SPE [41,111]. A large study by McGuire et al. (2017) used two consecutive SPE steps using C18
and PGC in sequence applying fluorescent labeling and HPLC analysis and still report 3-FL [68], but is
significantly lower quantities than another study using direct fluorescent labeling of untreated milk
followed by HPLC analysis [49,53]. In a recent study, by Kunz et al. (2017), graphitized carbon SPE was
used, followed by quantitative high pH anion exchange chromatography with pulsed amperometric
detection (HPAEC-PAD) analysis. Here 3-FL was reported to co-elute with LNDFH I, however in the
non-Secretor sub-population of this study no 3-FL was reported, indicating that probably all 3-FL was
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lost during SPE clean-up of the samples. It should be noted that LNDFH I is a structure containing an
(α1–2)-linked fucose epitope and is thus absent in non-Secretor samples [56].
These observations raise the question whether there are other specific losses of structures when
using either PGC-SPE or C18-SPE as a sample preparation step.
Centrifugal Fat Separation
A large amount of studies on hMOS start with removing or reducing the lipid content of the milk
by centrifugation [44,57,73,81,107,108,114–117]. In some studies, the fat layer on top of the sample is
scooped off the milk, in other studies the clear liquid is pipetted into a new vial, carefully avoiding
transferral of fat to the new vial. Some studies follow this step with SPE to further remove fat [73,117],
while other studies consider a significant reduction of fat sufficient. Some researchers have chosen to
start with a larger sample volume than required, diluting the sample and then taking a fixed exact
amount of clear liquid under the fat-layer after centrifugation. This may be the most precise method
for defatting and if carefully executed has little risk for specific losses of hMOS or large variations in
residual fat levels. Using a plate-rotor in the centrifuge allows this step to be incorporated in 96-wells
plate high-throughput procedures [118].
Liquid Extraction
Some studies employ a traditional Folch extraction [119], with chloroform:methanol (2:1) to
remove fat, and incidentally reduce the protein load of the sample, extracting denatured protein in
the chloroform phase [4,57,101,113,120–122]. Such liquid extractions are more effective in removing
the fat layer than scooping the fat layer off centrifuged samples but are quite labor intensive to
perform. When separating the chloroform layer from the hydrophilic layer it is important to take all
the chloroform or be left with fat. If the researcher removes part of the water layer, together with the
chloroform layer, then part of the hMOS will be lost as well. In practice, this approach often requires
centrifugation to resolve the two phases properly. Although this approach is labor intensive and not
very suited to high-throughput approaches or handling many samples, there have been studies with
extensive sample sizes employing a Folch extraction [30].
Ultrafiltration
To avoid interference from proteins in the analysis of hMOS, an ultrafiltration step can also be
used. This approach involves centrifugal filters with a MW cut-off, most frequently 10 kDa filters are
used [78,81,108], but some studies employ 3 kDa [107,116] or 30 kDa [38,71]. Tonon et al. (2019) verified
the efficiency of the filters and found no significant losses of hMOS for which they had quantitative
references [81]. One of the risks in using centrifugal filters is clogging of the filter with solids, which
is mostly a practical problem, which can likely be avoided by preceding the ultrafiltration step with
centrifugal removal of fat, in which solids will mostly precipitate to the bottom of the vial.
Organic Solvent Precipitation
Another method of protein removal involves the use of organic solvents to precipitate the
proteins. A series of publications employed 1:1 mixing of milk with acetonitrile to precipitate the
protein. The clear liquid was used to analyze hMOS directly in an HPAEC-PAD based method of
analysis [51,54,79,105,123,124]. Other studies, like the early approaches of Kobata et al. (1969) [65]
used ice-cold ethanol precipitation to remove protein. An added advantage of the ethanol approach is
the partial lactose precipitation. Most oligosaccharides remain in solution in 67% ethanol. The most
studied hMOS do not appear to co-precipitate in this approach [118], but there has not been a detailed
study of the precipitate to determine if some of the larger size hMOS might be lost in this step. A third
option for precipitation with organic solvents involves acetone [5]. Our lab has recently shown in
N-glycan studies, however, that acetone has potential for precipitation of larger oligosaccharides and
particularly sialylated glycans, while smaller neutral glycans are less affected [125]. It might be a
limited problem in the size-range usually encountered in hMOS, but it would be recommendable to
verify the method.
One major advantage of organic-solvent precipitation steps is that they are compatible with
high-throughput approaches and also applicable in 96-wells formats. One example is a very rapid
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method, combining centrifugal defatting with ethanol precipitation of proteins in a 96-wells format [118].
For really large sample sets, which may be required to answer the currently most pressing questions on
diversity and functionality, it may be crucial to adopt a rapid 96-wells format approach. However, such
a high-throughput approach should be evaluated to ensure it does not suffer from losses of specific
hMOS, as was observed for PGC-SPE.
Gel Filtration Chromatography
In some of the earliest hMOS studies gel-permeation chromatography was used [65,126], mostly
to separate the hMOS from the disaccharide lactose. Kobata et al. (1969) commonly used Sephadex
G25 to achieve size-based separation of hMOS, and then studying the different size fractions separately.
Other studies pool all the fractions that are shown to be lactose free and analyze the pool [5,127,128].
Other column types have also been employed, e.g., Toyopearl HW50 [71,129] or Biogel P2 [52,121,122],
but the principle of size based separation is the same. One of the challenges of such a gel filtration
chromatography is to correctly isolate the broad peaks. There tends to be overlap between size-species.
Particularly lactose will overlap with tri- and tetrasaccharide-peaks. Eliminating all fractions containing
lactose will achieve a lactose-free hMOS pool but might incur specific losses of the smaller hMOS.
Another disadvantage of the gel filtration approach lies in the time limitations; gel filtration columns
work at low flow-rates and run-times can take between 1.5 and 32 h per sample [52,71,121,122,129].
This limitation is prohibitive towards larger sample sets and high-throughput analyses.
3.2.2. Analytical Methods
Analysis of the hMOS usually makes use of a separation technique, coupled to a form of detection,
that is capable of a semi-linear response curve for increasing analyte concentrations. Separation is
achieved by either liquid chromatography on hydrophilic-interaction (HILIC) or anion-exchange
chromatography (AEC) based column, or by capillary electrophoresis, which is based on the relation
between hydrodynamic volume of the analyte and the charge of the analyte. In case of capillary
electrophoresis, usually a multiply charged label (8-aminopyrene-1,3,6-trisulfonic acid; APTS) is used,
to ensure that all oligosaccharides carry a negative charge. The label of choice is also usually fluorescent,
to achieve sensitive detection.
To detect the oligosaccharides after separation there is a choice between labelled (fluorescent or UV
active labels covalently coupled to the oligosaccharides) and label-free detection, e.g., refractive index
(RI), evaporative light scattering detection (ELSD), pulsed-amperometric detection (PAD), and mass
spectrometry (MS). Since RI has limited sensitivity and is limited to isocratic separation conditions, this
detection strategy is not feasible. Similarly, ELSD will suffer from limited compatibility with common
oligosaccharide separation gradients. This means that label-free detection is essentially limited to
PAD and MS. Some studies, however, employ UV detection of unlabeled sialylated structures, but the
sensitivity is limited and some of the most abundant neutral oligosaccharides cannot be detected in
this way (e.g., 2’-FL and 3-FL).
Liquid Chromatography
An attractive way to overcome this problem of detection, particularly for neutral oligosaccharides,
is the addition of a fluorescent label via reductive amination. Each oligosaccharide molecule acquires
one fluorescent label on the reducing end, most frequently 2-aminobenzamide (2-AB) or 2-aminobenzoic
acid (2-AA), but 2-aminoacridone (2-AMAC) has also been used. Since each molecule carries a single
fluorescent label, there is in essence an equal and linear response for each structure [130]. This eliminates
response factors in the detection, although differences in labeling efficiency between hMOS seem to
exist, resulting in calibration curves for standards with different slopes [104]. The highest and lowest
curve slopes in the study by Austin and Bénet showed a factor ~1.3 difference. Maltotriose had a slope
close to the means of all slopes, which makes this a good general calibrant, also suitable for structures
of which standards are not available.
There have also been some alternative labeling approaches to achieve detection, including
per-benzoylation of isolated oligosaccharides [75], to increase the UV absorbance of hMOS, as well
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as allowing C18 chromatography separation. Care must be taken to avoid under-benzoylation and
non-homogeneous labeling efficiency is a potential risk in such an approach. Several quantitative
studies have employed a UV-active label 1-phenyl-3-methyl-5-pyranozolone (PMP) to label the reducing
end of hMOS and achieving sensitive detection [4,101,121,122].
Capillary Electrophoresis
Separation of glycan structures by capillary electrophoresis (CE) has been established for protein
glycans [131]. To ensure that all glycans carry a negative charge, to make them active in electrophoresis,
it is common to attach a charges label, usually 8-Aminopyrene-1,3,6-trisulfonic acid, but also 2-AA and
2-AMAC are suitable for this purpose [124]. One study has used CE on sialylated glycans [40,82,117],
and detected them by the UV-absorption of the N-acetyl groups [114].
One of the main challenges in CE is that the migration-rate through the column is proportional to
the size—charge ratio. This means that structural isomers will co-elute, e.g., 2′-FL and 3-FL; LNT and
LNnT, will co-elute. Therefore, studies employing CE can only report quantities of these structures
together. In some cases, the structural isomers have a slightly different hydrodynamic volume, and are
slightly separated on the column. Using proper settings allows sufficient separation to quantify these
structures separately. Galeotti et al. (2014) were not able to separate LNFP II and LNFP III, but both
were separated sufficiently from LNFP I. In the same study 2′-FL and 3-FL were separated, but 3′-SL
and 6′-SL were not [124]. Another study, by Olivares et al. (2015), was able to separate LNFP II, but
LNFP I and III co-eluted, similarly, co-elution was observed for 2′-FL with 3-FL, LNT with LNnT and
3′-SL with 6′-SL [117]. Although other separation techniques also have occasional co-eluting species,
the level of co-elution on CE is much more prominent. This is one of the major drawbacks of CE
approaches. The advantages of CE are the easy coupling to mass spectrometry, rapid analysis times,
and very sharp peaks.
HPAEC-PAD
Finally, there is another chromatographic method that requires no labeling. Here, oligosaccharides
are separated in a high pH chromatography system. At the high pH employed, the hydroxyl groups
are deprotonated and the difference in pKa of the various hydroxyls plays an important role in
the separation properties on an anion-exchange column (HPAEC) [132,133]. An added advantage
of the high-pH based deprotonation of hydroxyls is the possibility to detect the oligosaccharides
with pulsed-amperometric detection (PAD). One of the major disadvantages is that the differential
deprotonation of oligosaccharides also induces a vast range of response factors on the detector [134,135].
Different studies on hMOS have reported vastly different response factor ranges, but this may be
the result of different chromatography gradients, as the response factor is strongly pH dependent
and a difference in elution gradient may induce a difference of pH when a specific oligosaccharide is
eluted [50,54,134,135]. This means that each lab will have to determine response factors themselves,
and due to minor changes in buffers between runs each new analysis requires a new response-factor
determination to be precise in results. Another disadvantage of the PAD-detection is the relatively
limited linearity in detector response [132,133]. One way to cover this, is by injecting samples in two
different concentrations to quantify major and medium compounds separately, Kunz et al. (2017)
have alternatively employed a quadratic calibration curve [56]. This overcomes the limitations in
linearity, but at higher concentrations the standard deviation in concentration derived from a certain
integration increases.
These limitations notwithstanding, there are several studies using HPAEC-PAD and reaching
quantitative results with good repeatability within their own lab. Moreover, the quantities reported
in some of the studies are well within reach of most other reports [1,56,78]. Other studies using
HPAEC-PAD, employing a 3-point calibration curve for some references, report relatively high
values [50,54,105]. A comparison between methods from one of these studies showed rather high
differences between analysis by HPAEC-PAD, LC coupled to a laser-induced fluorescence (LIF) detector
or LC–MS approaches [105], although the HPAEC-PAD showed the lowest total hMOS concentrations
in most cases. A later study using CE-LIF also reported high values for the same samples [124].
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All studies on this sample set employed a protein precipitation step with 50% acetonitrile as sole
extraction step. For fluorescence detection and MS analysis the samples were labelled via reductive
amination, and for HPAEC-PAD no labeling was employed. All reported values with the different
studies are well above generally reported ranges [1]. Whether this is specific to this set of samples
from Italy, or an experimental bias is unknown.
NMR Spectroscopy
A more rare method is NMR based metabolomics, which does not add a separating technique, but
instead focuses on specific combinations of bins in the NMR spectrum indicative of specific structural
elements [106,107]. A more detailed structural-reporter-group concept has also been developed in
the past also for N- and O-glycans [136,137]. In our lab we found that specific structures, with the
exception of 2′-FL, were not readily detected and quantified by NMR spectroscopy of an isolated
hMOS pool [73]. Most similar structures overlap, e.g., all hMOS bearing a Lewisb epitope showed
overlapping structural-reporter-group signals. The sole exception was 2′-FL, for which a specific
structural-reporter signal was available. General structural identities can be analyzed quantitatively,
and distinction between the different Lewis epitopes, H-antigen and sialic acid elements could be made
effectively [36]. In metabolomics studies, usually no clean-up steps are applied or as few as possible.
Minimal sample treatment avoids specific losses of structures, such as loss of 3-FL by graphitized
carbon SPE. However, many other components of the biological sample will render overlapping peaks,
increasing the difficulty in selectivity and quantitation of specific hMOS structure groups.
Mass Spectrometry-Based Methods
In mass spectrometry there is a difference in discovery driven “shotgun” approaches, where
quantitation and repeatability of results are generally limited, while identification of new biomolecules
is very high [138]. In targeted analyses the repeatability and quality of quantitation is much improved.
However, there is still the question of reproducibility, i.e., the same sample analyzed by another operator
or another lab on a similar system, reaching the same result [139]. The challenges of mass spectrometry
based quantitation are well described for proteomics approaches [138,139], but not exhaustively yet for
carbohydrate analyses. However, some basic principles apply to any MS approach. There is a difference
between mass spectrometer sensitivity and the limit of detection (LOD). Sensitivity of the machine
is determined by the minimum amount of pure analyte required to elicit a response on the detector.
The LOD is also influenced by the signal-to-noise level achieved in the context of the sample matrix
and elution conditions. In transition monitoring methods, increased amount of transitions increases
the noise level, and therefore negatively influences the LOD [139]. The dynamic and linear ranges
of machines are also relevant; if a mass detector gets saturated for main compounds, before minor
compounds of interest can be effectively quantified, the dynamic range is too limited. Alternatively,
two different concentrations can be measured to cover both major, and minor compounds. In general,
in-beam instruments have a better dynamic range than ion-trap instruments, due to increases in
noise levels in longer trapping times. Furthermore, calibration curves are usually determined using
pure compounds dissolved in pure solvents, while real biological samples have matrix contaminants
that can induce ion-suppression [140]. Co-eluting compounds and background therefore influences
ionization efficiency (ionization suppression and ionization enhancement) and dynamic range of the
analytes of interest. In-spiking of isotope-labelled standards for quantitation is still the golden standard,
but some advancements in machines, methods and software have improved label-free quantitation
significantly in the last decade [138]. If proper steps are taken, good quantitation with MS is possible,
also without isotope-labeling, reaching accuracies within 15% deviation [111,141,142]. Many of the
most recent LC-MS based quantitative approaches achieve hMOS values comparable with most other
studies [41,111,141].
4. Conclusions
Taking all these factors into account, it is very difficult to compare different studies. As established
there are great differences in methods employed to analyze hMOS. Some studies use a very elaborate
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sample treatment prior to analysis and quantitation of hMOS, while others have very simple approaches.
It is important to realize that most sample treatment steps have a risk of specific losses of some hMOS
structures or introduction of methodological biases. As shown by Xu et al. (2017), the application
of porous graphitized carbon SPE columns led to the specific loss of 3-FL [111]. One study assessed
specifically that no bias in structures was induced by ultrafiltration [78]. However, most other
separation techniques have not been extensively assayed for specific losses of hMOS.
It is also important to note that some analytical approaches are essentially better suited to
quantitative analysis than other. Although the difficulties of HPAEC-PAD quantitation can be
overcome with very good reference calibration curves to determine response factors and to cover lack
of linearity in dose-response with quadratic curves, detection of fluorescently labelled oligosaccharides
with a large linear response range is essentially better suited for quantitative analysis. While MS
has good potential for long linear ranges, there is the problem of response factors to contend with.
Essentially, only oligosaccharides for which a reference standard is available can be effectively
quantified. Additionally, steps have to be taken to assess possible matrix associated loss of sensitivity
and ion-suppression/enhancement.
Even when using fluorescent labeling via reductive amination of free oligosaccharides, and as
few sample treatment steps as possible, there is still a difference in labeling efficiency to be taken into
account [104]. In this case, however, the response factors for different oligosaccharides seems to be
limited. The level of accuracy of the method using an internal maltotriose standard rather than true
hMOS references still achieved spike-in recoveries within acceptable levels of deviation [104].
To close, I would like to repeat the recommendation by Thurl et al. (2017), that a double-blind
multi-center study of hMOS analysis would be very beneficial to assess the true levels of hMOS
in human milk [1]. This will help assess how big the variation in hMOS composition is between
milk groups, between individuals within a geographical region, but also between the regions of the
world. Moreover, it would be beneficial to also assess efficacy of the different analytical approaches for
analyses in blood, urine, feces, and amniotic fluid. The next steps forward in hMOS research would
strongly benefit from solid quantitative data in all relevant biological matrices.
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